Researchers are revisiting old drugs and designing new ones to prevent and treat COVID.
Academic rigor, journalistic flair
Articles on COVID-19 treatment
Displaying 1 - 20 of 24 articles
Early on, public health messaging focused on the need for vaccines to combat COVID-19. But far less attention has been given to the role of boosters in preventing deaths and reducing inequities.
The key to supporting science innovation is funding and shaping it at its earliest stages, while innovative ventures are still housed within universities — and even before the ventures are founded.
They’re calling for advice before using bleach or disinfectant. Or they’re calling to ask about side-effects after gargling, spraying or bathing in them. It’s a worry.
Plasma therapy sounded great at the start of the pandemic. Give COVID patients blood plasma from people who had recovered. But the evidence is in. It doesn’t work.
A lot has changed in COVID treatment since the pandemic began. Here are the treatments you can expect — from being diagnosed, to going to hospital, and for those who need to be cared for in ICU.
Ivermectin is the most recent example of a medication touted as a miracle drug for COVID-19 without solid medical evidence supporting its use.
Side-effects for this unproven and potentially dangerous treatment range from vomiting and diarrhoea to seizures and a coma.
The government has ordered 7,700 doses of sotrovimab. But until further evidence shows it’s effective, the guidelines say it should only be given to patients as part of a human clinical trial.
Investigations have led to the withdrawal of a study backing ivermectin to treat COVID-19. But that’s not the last time we’ll hear about this controversial drug.
Researchers around the world are using new and existing technology to develop potential treatments for those with COVID-19. Here’s what’s in development in Australia.
While the results are very promising, it has only been tested in mice. Human clinical trials will take some time to complete before we know whether a drug could become available.
In the blood of COVID-19 survivors are antibodies that can defeat SARS-CoV-2. Researchers are testing whether these antibodies can be collected and injected into others to save them from the virus.
The head lice drug ivermectin is being touted as a coronavirus killer. But studies suggest it would need to be taken in mega-doses far higher than those currently used, with unknown side-effects.
Nanoparticles dressed up in cell membranes snag SARS-CoV-2 virus particles before they reach human cells.
Word that the U.S. has bought up the entire supply of the COVID-19 drug remdesivir is another reminder that in a pandemic, treatments and vaccines need to be accessible to everyone, globally.
During the last six months, news reports have mentioned dozens of drugs that may be effective against the new coronavirus. Here we lay out the evidence and reveal which ones are proven to work. Or not.
Scientists have discovered that a widely used, cheap steroid can fight off COVID-19 in the most severe cases. Here’s how it works.
Antibodies that recognize and block SARS-CoV-2 infection have the potential to be powerful weapons. An infectious disease expert explains what antibodies are and how they could be used as a therapy.
A lot depends on China and India sharing the products of their pharmacuetical manufacturing with the rest of the world.
Top contributors
-
Head of School and Dean of Pharmacy, University of Sydney
-
Associate Professor of the School of Pharmacy, University of Sydney
-
Professor, Head of School, School of Architecture, University of Technology Sydney
-
Lecturer in Virology, Queen's University Belfast
-
Senior Lecturer, University of Sydney
-
Executive Director, National COVID-19 Clinical Evidence Taskforce, and Professor, School of Public Health and Preventive Medicine, Monash University
-
Senior Lecturer in Chemical Pathology, University of Westminster
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Senior Lecturer, Global Development Institute, University of Manchester
-
Professional Research Fellow, Victoria University
-
Professor of Medicine, University of Virginia
-
Senior Lecturer, University of Sydney
-
Emergency Physician and Clinician Scientist, University of Toronto
-
Director, Evidence and Methods, National COVID-19 Clinical Evidence Taskforce; Associate Professor (Research), Cochrane Australia, School of Population Health and Preventive Medicine, Monash University, Monash University
